Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Organon & Co. Common Stock — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.27 (market cap $5.70B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 63 Days and Organon & Co. Common Stock for 0 Days on average.
| JNK | OGN | |
|---|---|---|
Market Cap | $5.70B | $3.62B |
Volume | 1,722,684 | 2,892,999 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $13.81 |
52-Week Low | $92.25 | $5.70 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.66, down 0.29% amid a bearish technical outlook with selling pressure across moving averages and oscillators. The ETF shows consistent dividend payments of $0.53 but lacks fundamental ratio data. Recent market focus centers on rising bond yields and geopolitical tensions affecting high-yield bond markets.
Outlook remains cautious as technical indicators signal bearish momentum with RSI at overbought levels. Investment opportunities include steady dividend income, while risks involve sensitivity to interest rate hikes and broader bond market volatility. The ETF's performance is closely tied to credit market conditions.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
